Contrasting Baxalta (BXLT) & Its Rivals

Baxalta (NYSE: BXLT) is one of 48 publicly-traded companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Baxalta to related companies based on the strength of its profitability, risk, dividends, valuation, earnings, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

42.7% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 15.3% of shares of all “Biopharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Baxalta and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Baxalta 9.37% 14.28% 4.62%
Baxalta Competitors -13,486.12% -54.03% -24.46%

Earnings & Valuation

This table compares Baxalta and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Baxalta N/A N/A 38.67
Baxalta Competitors $584.27 million $101.79 million 73.25

Baxalta’s competitors have higher revenue and earnings than Baxalta. Baxalta is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Dividends

Baxalta pays an annual dividend of $0.28 per share and has a dividend yield of 0.6%. Baxalta pays out 23.5% of its earnings in the form of a dividend. As a group, “Biopharmaceuticals” companies pay a dividend yield of 0.6% and pay out 23.5% of their earnings in the form of a dividend. Baxalta has increased its dividend for 2 consecutive years.

Analyst Recommendations

This is a summary of recent ratings and price targets for Baxalta and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Baxalta 0 0 0 0 N/A
Baxalta Competitors 158 826 1811 61 2.62

As a group, “Biopharmaceuticals” companies have a potential upside of 2.68%. Given Baxalta’s competitors higher probable upside, analysts plainly believe Baxalta has less favorable growth aspects than its competitors.

Summary

Baxalta competitors beat Baxalta on 5 of the 8 factors compared.

About Baxalta

Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta’s categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.

Receive News & Ratings for Baxalta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxalta and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.